BRPI0715017A8 - composições e métodos relativos aos anticorpos receptores de glucagon - Google Patents

composições e métodos relativos aos anticorpos receptores de glucagon Download PDF

Info

Publication number
BRPI0715017A8
BRPI0715017A8 BRPI0715017A BRPI0715017A BRPI0715017A8 BR PI0715017 A8 BRPI0715017 A8 BR PI0715017A8 BR PI0715017 A BRPI0715017 A BR PI0715017A BR PI0715017 A BRPI0715017 A BR PI0715017A BR PI0715017 A8 BRPI0715017 A8 BR PI0715017A8
Authority
BR
Brazil
Prior art keywords
methods
glucagon receptor
receptor antibody
antibodies
antibody compositions
Prior art date
Application number
BRPI0715017A
Other languages
English (en)
Inventor
Thomas C Boone
Shaw-Fen Sylvia Hu
Richard A Lindberg
Hai Yan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0715017A2 publication Critical patent/BRPI0715017A2/pt
Publication of BRPI0715017A8 publication Critical patent/BRPI0715017A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

composições e métodos relativos aos anticorpos receoptores de glucagon. a presente revelação fornece as composições e métodos relacionados às proteinas de ligação ao antígeno, em particular os anticorpos que especificamente se ligam ao receptor de glucagon humano. a revelação fornece os ácidos nucléicos que codificam tais proteínas de ligação ao antígeno e anticorpo e os métodos para produzir e utilizar tais anticorpos, incluindo os métodos para tratar e prevenir o diabetes tipo 2 e distúrbios associados, administrando tais anticorpos a um sujeito que necessite de tal tratamento.
BRPI0715017A 2006-09-20 2007-09-19 composições e métodos relativos aos anticorpos receptores de glucagon BRPI0715017A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84620206P 2006-09-20 2006-09-20
US60/846,202 2006-09-20
US96897707P 2007-08-30 2007-08-30
US60/968,977 2007-08-30
PCT/US2007/020349 WO2008036341A2 (en) 2006-09-20 2007-09-19 Compositions and methods relating to glucagon receptor antibodies

Publications (2)

Publication Number Publication Date
BRPI0715017A2 BRPI0715017A2 (pt) 2013-05-28
BRPI0715017A8 true BRPI0715017A8 (pt) 2018-04-03

Family

ID=39201088

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715017A BRPI0715017A8 (pt) 2006-09-20 2007-09-19 composições e métodos relativos aos anticorpos receptores de glucagon

Country Status (19)

Country Link
US (2) US7947809B2 (pt)
EP (1) EP2074149B1 (pt)
JP (1) JP5513888B2 (pt)
KR (1) KR20090059161A (pt)
CN (1) CN101589062B (pt)
AR (1) AR062895A1 (pt)
AU (1) AU2007297652B2 (pt)
BR (1) BRPI0715017A8 (pt)
CA (1) CA2662613C (pt)
CL (1) CL2007002668A1 (pt)
CR (1) CR10736A (pt)
EA (1) EA200970262A1 (pt)
ES (1) ES2444012T3 (pt)
IL (1) IL197241A0 (pt)
MX (2) MX353319B (pt)
NO (1) NO20091534L (pt)
PE (1) PE20080846A1 (pt)
TW (1) TW200820985A (pt)
WO (1) WO2008036341A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070844A1 (es) * 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
WO2011030935A1 (en) * 2009-09-08 2011-03-17 Neopharm Co., Ltd. Antibodies against glucagon receptor and their use
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
CA2923145C (en) 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
CA3104268A1 (en) * 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
CA2963166C (en) * 2014-10-01 2023-10-03 Medimmune Limited Antibodies to ticagrelor and methods of use
CN105669863B (zh) * 2014-12-05 2019-09-13 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
WO2016102657A1 (en) 2014-12-23 2016-06-30 Novo Nordisk A/S Alpha-cell re-generation combined with conversion to beta cells
AR103442A1 (es) 2015-01-16 2017-05-10 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos de ror1
KR20170138456A (ko) 2015-04-02 2017-12-15 렘드 바이로테라퓨틱스, 인크 글루카곤 수용체 길항 항체를 이용한 비만 및 비알콜성 지방간 질환 또는 비알콜성 지방간염의 치료 방법
CA2999747A1 (en) 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
WO2017062693A1 (en) * 2015-10-07 2017-04-13 Remd Biotherapeutics, Inc. Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
WO2017120261A1 (en) * 2016-01-04 2017-07-13 Remd Biotherapeutics, Inc. Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
WO2018027084A2 (en) * 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
BR112019015479A2 (pt) 2017-01-27 2020-03-31 Ngm Biopharmaceuticals, Inc. Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
JP2020510646A (ja) * 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN107011414B (zh) * 2017-05-31 2020-04-24 浙江省农业科学院 具有降血糖功能的三肽spf及其用途
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN119639849A (zh) 2018-03-26 2025-03-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
FI3852617T3 (fi) 2018-09-20 2025-10-21 Sfj Pharma X Inc Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
CA3123979A1 (en) 2018-12-21 2020-06-25 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
US20220235140A1 (en) * 2019-05-29 2022-07-28 Hedgehog, Inc. Antibody with enhanced binding affinity for endothelin receptor type a
MX2022001882A (es) * 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US12391762B2 (en) * 2020-08-26 2025-08-19 Twist Bioscience Corporation Methods and compositions relating to GLP1R variants
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
US20240067740A1 (en) * 2020-12-31 2024-02-29 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
WO2022182664A1 (en) * 2021-02-23 2022-09-01 10X Genomics, Inc. A method for epitope binning of novel monoclonal antibodies
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026090253A1 (en) 2024-10-23 2026-04-30 Amgen Inc. Methods of determining glycan pairing content

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) * 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) * 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
WO2002045494A2 (en) 2000-12-06 2002-06-13 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
ES2371083T3 (es) * 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta

Also Published As

Publication number Publication date
AR062895A1 (es) 2008-12-10
KR20090059161A (ko) 2009-06-10
PE20080846A1 (es) 2008-08-23
IL197241A0 (en) 2011-08-01
ES2444012T3 (es) 2014-02-21
US8158759B2 (en) 2012-04-17
AU2007297652A1 (en) 2008-03-27
EP2074149B1 (en) 2013-11-06
CN101589062A (zh) 2009-11-25
NO20091534L (no) 2009-04-28
US20110223160A1 (en) 2011-09-15
TW200820985A (en) 2008-05-16
JP2010504331A (ja) 2010-02-12
CL2007002668A1 (es) 2008-05-09
JP5513888B2 (ja) 2014-06-04
CR10736A (es) 2009-06-30
WO2008036341A3 (en) 2009-02-05
AU2007297652B2 (en) 2012-02-16
US20090041784A1 (en) 2009-02-12
BRPI0715017A2 (pt) 2013-05-28
MX2009003093A (es) 2009-06-05
CA2662613A1 (en) 2008-03-27
WO2008036341A2 (en) 2008-03-27
EA200970262A1 (ru) 2009-10-30
CN101589062B (zh) 2014-08-20
US7947809B2 (en) 2011-05-24
EP2074149A2 (en) 2009-07-01
MX353319B (es) 2018-01-05
CA2662613C (en) 2014-01-28

Similar Documents

Publication Publication Date Title
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112012007294A2 (pt) moléculas de ligação a dll4
NO20083793L (no) Antistoffer mot amyloid-beta peptid
CO7250445A2 (es) Proteínas de unión a antígeno st2
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
ECSP12011698A (es) Anticuerpos cea
BR112013028655A8 (pt) Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos
EA201691176A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ
BRPI0905761A2 (pt) Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
CL2009000586A1 (es) Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
NZ597694A (en) Anti-IGF antibodies
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
BRPI0415195A (pt) anticorpos completamente humanos contra 4-1bb humana (cd137)
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
EA201290630A1 (ru) Лечение расстройства обмена веществ
HK1132751A (en) Compositions and methods relating to glucagon receptor antibodies
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
EA201991493A3 (ru) Антиген-связывающие белки человека, которые связываются с β-клото, рецепторами fgf и их комплексами

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]